TY - DATA T1 - Supplementary Material for: Anemia Management in the China Dialysis Outcomes and Practice Patterns Study PY - 2016/03/31 AU - Zuo L. AU - Wang M. AU - Hou F. AU - Yan Y. AU - Chen N. AU - Qian J. AU - Bieber B. AU - Pisoni R.L. AU - Robinson B.M. UR - https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Anemia_Management_in_the_China_Dialysis_Outcomes_and_Practice_Patterns_Study/5129164 DO - 10.6084/m9.figshare.5129164.v1 L4 - https://ndownloader.figshare.com/files/8717653 KW - China KW - Domestic erythropoietin stimulating agents KW - End-stage renal disease-related anemia KW - Intravenous iron N2 - Background: As the utilization of hemodialysis increases in China, it is critical to examine anemia management. Methods: Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we describe hemoglobin (Hgb) distribution and anemia-related therapies. Results: Twenty one percent of China's DOPPS patients had Hgb <9 g/dl, compared with ≤10% in Japan and North America. A majority of medical directors targeted Hgb ≥11. Patients who were female, younger, or recently hospitalized had higher odds of Hgb <9; those with insurance coverage or on twice weekly dialysis had lower odds of Hgb <9. Iron use and erythropoietin-stimulating agents (ESAs) dose were modestly higher for patients with Hgb <9 compared with Hgb in the range 10-12. Conclusion: A large proportion of hemodialysis patients in China's DOPPS do not meet the expressed Hgb targets. Less frequent hemodialysis, patient financial contribution, and lack of a substantial increase in ESA dose at lower Hgb concentrations may partially explain this gap. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=442741. ER -